At a glance
ClinicalIndex Comparison RecordN/ACompleted· 333 enrolled
Drug / intervention
Restylane-L®device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Evaluator-blinded, Parallel Group, No-treatment Controlled, Multi-center Study to Evaluate the Safety and Effectiveness of Restylane-L® for Correction of Infraorbital Hollows
In Brief
A clinical study evaluating Restylane-L® for Infraorbital Hollows. Completed, enrolled 333 participants across 16 sites.
Detailed Summary
This is a prospective, randomized, evaluator-blinded, no-treatment controlled, parallel group, multi-center US study to evaluate the safety and effectiveness of Restylane-L® for correction of Infraorbital Hollows.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfraorbital Hollows
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
First PostedNov 2019
Enrollment StartNov 2019
Primary CompletionJan 2021
Study CompletionApr 2022
TodayJul 2026
First PostedNov 7, 2019
Enrollment StartNov 11, 2019
Primary CompletionJan 31, 2021
Study CompletionApr 6, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 6.7 years ago
Interventions
Restylane-L®device
Intradermal injection.